Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Precision Drilling Corp
NYSE:PDS
|
CA |
|
G
|
Greenbank Capital Inc
CNSX:GBC
|
CA |
|
H
|
Hwa Tai Industries Bhd
KLSE:HWATAI
|
MY |
|
JSL SA
BOVESPA:JSLG3
|
BR |
|
Prysmian SpA
MIL:PRY
|
IT |
|
Viva Energy Group Ltd
ASX:VEA
|
AU |
Novan Inc
Cash from Operating Activities
Novan Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Cash from Operating Activities
-$30.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$24.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$14.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
21%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$11.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$16.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
19%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Cash from Operating Activities?
Cash from Operating Activities
-30.9m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Cash from Operating Activities amounts to -30.9m USD.
What is Novan Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-1%
Over the last year, the Cash from Operating Activities growth was -25%. The average annual Cash from Operating Activities growth rates for Novan Inc have been -16% over the past three years , -1% over the past five years .
